In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, contributors will acquire ABBV-744 and ruxolitinib. Contributors will get treatment right up until sickness progression or maybe the contributors are unable to tolerate the study drugs. Attainable new strategies for your prognosis and treatment of AML. (A) https://alvab332ozj5.birderswiki.com/user